Connect with us
  • Elysium


IRLAB: Developing drug candidates with ‘blockbuster potential’ in Parkinson’s

Gunnar Olsson, CEO of Swedish biotech company, IRLAB, speaks to NR Times about its ‘blockbuster’ drug candidates which aim to tackle major unmet needs in neurodegenerative diseases. 



Parkinson’s is the most common primary neurodegenerative disease after Alzheimer’s, affecting nearly nine million people around the world. This figure is expected to double by 2040 in line with an ageing population. 

Rooted in the Nobel Prize-winning research of Professor Arvid Carlsson, who was best known for his work exploring the role of the neurotransmitter dopamine in Parkinson’s, IRLAB, is developing innovative treatments to tackle unmet needs in Parkinson’s and other neurodegenerative conditions. 

Subscribe to read the full interview

Read this and more exclusive content every day as an NR Times online subscriber. Just £2.99 a month, cancel anytime.

Login Join Now